Drug Trial Radar · NCT02038647
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Last checked: Nov 19, 2026Latest source record: Dec 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
May 12, 2014
Primary completion
Jan 3, 2016
Study completion Jul 10, 2017
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.
Conditions
- Small Cell Lung Cancer
Interventions
AlisertibDrug
Alisertib tablets
PlaceboDrug
Placebo matching tablets
PaclitaxelDrug
Paclitaxel intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA GuidelinesTime frame: Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)
Locations
61 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
New Haven, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Hollywood, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Cleveland, Ohio
Site not named
Hershey, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Seattle, Washington
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Leuven, Belgium
Site not named
Mons, Belgium
Site not named
Roeselare, Belgium
Site not named
Greenfield Park, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Olomouc, Czechia
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Grenoble, France
Site not named
Lyon, France
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Pessac, France
Site not named
Rennes, France
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.